Proinflammatory consequences of transgenic Fas ligand expression in the heart

Journal of Clinical Investigation

Volumn 105, Issue 9, 2000, Pages 1199-1208

  Nelson, David P ^a   Setser, Elizabeth ^a   Hall, D Greg ^b   Schwartz, Steven M ^a   Hewitt, Timothy ^a   Klevitsky, Raisa ^a   Osinska, Hanna ^a   Bellgrau, Don ^c,d   Duke, Richard C ^c,d   Robbins, Jeffrey ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Ceres Pharmaceuticals Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIGAND; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CELL VOLUME; GENE EXPRESSION; HEART; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEUKOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 12944312764     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8212     Document Type: Article

References (43)

1. Nagata, S., and Golstein, P. 1995. The Fas death factor. Science. 267:1449-1456.
2. Green, D.R., and Ware, C.F. 1997. Fas-ligand: privilege and peril. Proc. Natl. Acad. Sci. USA 94:5986-5990.
3. Takahashi, T., et al. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969-976.
4. Lynch, D.H., et al. 1994. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity. 1:131-136.
5. Seino, K., et al. 1997. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology. 113:1315-1322.
6. Baker, M.B., Altman, N.H., Podack, E.R., and Levy, R.B. 1996. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med. 183:2645-2656.
7. Yamada, K., et al. 1996. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia. 39:1306-1312.
8. Itoh, N., et al. 1997. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186:613-618.
9. Chervonsky, A.V., et al. 1997. The role of Fas in autoimmune diabetes. Cell. 89:17-24.
10. Giordano, C., et al. 1997. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 275:960-963.
11. Bellgrau, D., et al. 1995. A role for CD95 ligand in preventing graft rejection. Nature. 377:630-632.
12. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., and Ferguson, T.A. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
13. Hahne, M., et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1363-1366.
14. O'Connell, J., Bennett, M.W., O'Sullivan, G.C., Collins, J.K., and Shanahan, F. 1997. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol. Med. 3:294-300.
15. Bennett, M.W., et al. 1998. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160:5669-5675.
16. Lau, H.T., Yu, M., Fontana, A., and Stoeckert, C.J., Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science. 273:109-112.
17. Zhang, H., et al. 1997. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J. Clin. Invest. 100:1951-1957.
18. Sata, M., et al. 1998. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc. Natl. Acad. Sci. USA. 95:1213-1217.
19. Swenson, K.M., et al. 1998. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation. 65:155-160.
20. Li, X.K., et al. 1998. Prolonged survival of rat liver allografts transferred with Fas ligand-expressing plasmid. Transplantation. 66:1416-1423.
21. Arai, H., Gordon, D., Nabel, E.G., and Nabel, G.J. 1997. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA. 94:13862-13867.
22. Seino, K., Kayagaki, N., Okumura, K., and Yagita, H. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165-170.
23. Allison, J., Georgiou, H.M., Strasser, A., and Vaux, D.L. 1997. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA. 94:3943-3947.
24. Kang, S.M., et al. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738-743.
25. Kang, S.M., et al. 1997. Immune response and myoblasts that express Fas ligand. Science. 278:1322-1324.
26. Chen, J.J., Sun, Y., and Nabel, G.J. 1998. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 282:1714-1717.
27. Ottonello, L., Torrolina, G., Amelotti, M., and Dallegri, F. 1999. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 162:3601-3606.
28. Seino, K., et al. 1998. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161:4484-4488.
29. Subramaniam, A., et al. 1991. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J. Biol. Chem. 266:24613-24620.
30. Gulick, J., et al. 1997. Transgenic remodeling of the regulatory myosin light chains in the mammalian heart. Circ. Res. 80:655-664.
31. Gerdes, A.M., Onodera, T., Wang, X., and McCune, S.A. 1996. Myocyte remodeling during the progression to failure in rats with hypertension. Hypertension. 28:609-614.
32. Takeuehi, T., et al. 1999. Accelerated rejection of Fas ligand-expressing heart grafts. J. Immunol. 162:518-522.
33. Sata, M., and Walsh, K. 1998. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat. Med. 4:415-420.
34. Yokoyama, T., et al. 1997. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 95:1247-1252.
35. Mann, D.L., and Young, J.B. 1994. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 105:897-904.
36. Palmer, J.N., Hartogensis, W.E., Patten, M., Fortuin, F.D., and Long, C.S. 1995. Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J. Clin. Invest. 95:2555-2564.
37. Bozkurt, B., et al. 1998. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97:1382-1391.
38. Mann, D.L. 1996. The effect of tumor necrosis factor-alpha on cardiac structure and function: a tale of two cytokines. J. Card. Fail. 2(Suppl.):S165-S172.
39. Kubora, T., et al. 1997. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. 81:627-635.
40. Bryant, D., et al. 1998. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 97:1375-1381.
41. Wilson, D.J., et al. 1996. JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in human T cells. Eur. J. Immunol. 26:989-994.
42. Brenner, B., et al. 1997. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J. Biol. Chem. 272:22173-22181.
43. Chen, C.Y., and Faller, D.V. 1999. Selective inhibition of protein kinase C isozymes by Fas ligation. J. Biol. Chem. 274:15320-15328.